Protagonist Therapeutics (PTGX) Revenue (2017 - 2026)

Protagonist Therapeutics (PTGX) has 10 years of Revenue data on file, last reported at $56.4 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 99.03% year-over-year to $56.4 million; the trailing twelve-month figure through Mar 2026 stood at $74.1 million (down 63.36% YoY), and the FY2025 full-year result was $46.0 million, down 89.41% from the prior year.
• Revenue improved to $56.4 million in Q1 2026, from $7.4 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $255.0 million in Q1 2024 to a low of $859000.0 in Q2 2022.
• A 5-year average of $50.6 million and a median of $16.6 million in 2022 frame the typical range for Revenue.
• Across the five-year window, Revenue soared 315.61% in 2022 and sank 95.49% in 2025, its largest moves.
• Tracing PTGX's Revenue over 5 years: stood at $859000.0 in 2022, then surged by 5720.72% to $50.0 million in 2023, then soared by 230.0% to $165.0 million in 2024, then slumped by 95.49% to $7.4 million in 2025, then soared by 657.94% to $56.4 million in 2026.
• Business Quant data shows PTGX's Revenue at $56.4 million in Q1 2026, $7.4 million in Q4 2025, and $4.7 million in Q3 2025.